Novavax NVAX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$9.49M-154% | $17.53M+109% | -$202.38M-290% | $106.51M-79.5% | $518.65M+740% | ||
| $3.06M-40.3% | $5.13M-22.2% | $6.59M-12.9% | $7.56M-9.3% | $8.34M-33.4% | ||
| $7.72M-3.1% | $7.97M-6.8% | $8.55M-7.2% | $9.21M-10.4% | $10.29M-1.6% | ||
| $266K-67.0% | $807K-99.2% | $97.04M+27,705% | $349K— | $0— | ||
| $226K— | —— | $3.75M-6.4% | $4.01M+269% | -$2.38M— | ||
| -$60.08M-179% | -$21.54M+18.8% | -$26.54M+57.6% | -$62.64M+70.4% | -$211.85M-399% | ||
| -$86.24M— | —— | -$207.93M-223% | $168.81M+329% | -$73.87M-7,991% | ||
| $8.97M+789% | -$1.3M— | —— | —— | -$16.55M-192% | ||
| -$50.95M-2,053% | -$2.37M+79.8% | -$11.71M-141% | -$4.87M+99.2% | -$604M— | ||
| -$32.42M+17.9% | -$39.48M— | —— | -$127.46M+31.3% | -$185.5M-7.1% | ||
| $1.27M-38.8% | $2.08M+2.9% | $2.02M— | $0-100% | $1.6M-17.4% | ||
| $214.13M— | —— | $235.01M— | —— | $114.72M— | ||
| $147.29M+49.4% | $98.61M-1.9% | $100.5M-10.0% | $111.63M+160% | $43M-87.3% | ||
| -$28.36M— | —— | -$136.53M-223% | $111.1M+252% | -$73.32M— | ||
| $46.41M— | —— | —— | —— | $0— | ||
| $578K-90.8% | $6.27M+538% | $984K+60.8% | $612K-72.2% | $2.2M-20.1% | ||
| $37.68M— | —— | $42.44M+4,181% | -$1.04M+85.3% | -$7.06M— | ||
| -$18K— | —— | $658K-91.7% | $7.91M+950% | -$930K+91.3% | ||
| -$23.13M+15.3% | -$27.31M— | $0+100% | -$9.5M+96.4% | -$266.81M-516% | ||
| $6.29M+115% | $2.93M+27.2% | $2.31M-67.1% | $7.01M+150% | $2.8M-69.1% | ||
| $1.85M+30,683% | $6K-99.8% | $3.88M+13.3% | $3.42M+128% | $1.5M+387% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $266K-82.2% | $1.5M— | —— | —— | $0-100% | ||
| -$50.95M-2,053% | -$2.37M+79.8% | -$11.71M-141% | -$4.87M+99.2% | -$604M— | ||
| -$86.24M— | —— | -$207.93M-223% | $168.81M+329% | -$73.87M-7,991% | ||
| $8.97M+789% | -$1.3M— | —— | —— | -$16.55M-192% | ||
| $0— | $0-100% | $566K-48.7% | $1.1M+300% | $276K-73.9% | ||
| $1.27M-38.8% | $2.08M+2.9% | $2.02M— | $0-100% | $1.6M-17.4% | ||
| $147.29M+49.4% | $98.61M-1.9% | $100.5M-10.0% | $111.63M+160% | $43M-87.3% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $39.75M— | —— | —— | —— | $0— | ||
| $578K-90.8% | $6.27M+538% | $984K+60.8% | $612K-72.2% | $2.2M-20.1% | ||
| -$8.16M— | —— | —— | -$428K+91.2% | -$4.86M— | ||
| —— | -$1.2M0.0% | -$1.2M0.0% | -$1.2M0.0% | -$1.2M-468% | ||
| $1.85M+30,683% | $6K-99.8% | $3.88M+13.3% | $3.42M+128% | $1.5M+387% | ||
| -$33.69M+18.9% | -$41.55M— | —— | -$127.33M+31.9% | -$187.1M-6.9% | ||
| -$33.69M+18.9% | -$41.55M— | —— | -$127.33M+31.9% | -$187.1M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Novavax generate?
- Novavax (NVAX) generated -$384.9M in operating cash flow over the trailing twelve months.
- What is Novavax's free cash flow?
- After $5.4M of capital expenditures, Novavax's free cash flow was -$389.7M over the trailing twelve months, down 288.4% year over year.
- Where does Novavax's cash flow data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
